Clearside Biomedical, Inc. (CLSD)
NASDAQ: CLSD · Real-Time Price · USD
0.7750
+0.0150 (1.97%)
Jun 5, 2025, 4:00 PM - Market closed
Clearside Biomedical Stock Forecast
Stock Price Forecast
According to 5 professional analysts, the 12-month price target for Clearside Biomedical stock ranges from a low of $3.00 to a high of $6.00. The average analyst price target of $4.80 forecasts a 519.35% increase in the stock price over the next year.
Price Target: $4.80 (+519.35%)
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for Clearside Biomedical stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
Rating | Dec '24 | Jan '25 | Feb '25 | Mar '25 | Apr '25 | May '25 |
---|---|---|---|---|---|---|
Strong Buy | 3 | 3 | 3 | 3 | 3 | 3 |
Buy | 3 | 3 | 3 | 2 | 2 | 2 |
Hold | 0 | 0 | 0 | 0 | 0 | 0 |
Sell | 0 | 0 | 0 | 0 | 0 | 0 |
Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
Total | 6 | 6 | 6 | 5 | 5 | 5 |
Latest Forecasts
Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
---|---|---|---|---|---|---|---|
HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $6 → $5 | Strong Buy | Maintains | $6 → $5 | +545.16% | May 23, 2025 |
JMP Securities | JMP Securities | Buy Reiterates $5 | Buy | Reiterates | $5 | +545.16% | May 16, 2025 |
Needham | Needham | Strong Buy Maintains $4 → $3 | Strong Buy | Maintains | $4 → $3 | +287.10% | May 15, 2025 |
Needham | Needham | Strong Buy Reiterates $4 | Strong Buy | Reiterates | $4 | +416.13% | Apr 8, 2025 |
HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $6 | Strong Buy | Reiterates | $6 | +674.19% | Mar 31, 2025 |
Financial Forecast
Revenue This Year
1.13M
from 1.66M
Decreased by -32.21%
Revenue Next Year
6.51M
from 1.13M
Increased by 476.77%
EPS This Year
-0.43
from -0.47
EPS Next Year
-0.67
from -0.43
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
---|---|---|---|---|---|
High | 3.5M | 21.3M | 34.9M | ||
Avg | 1.1M | 6.5M | 14.8M | ||
Low | n/a | n/a | n/a |
Revenue Growth
Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
---|---|---|---|---|---|
High | 113.3% | 1,788.7% | 437.1% | ||
Avg | -32.2% | 476.8% | 127.8% | ||
Low | - | - | - |
EPS Forecast
EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
---|---|---|---|---|---|
High | -0.25 | -0.21 | -0.24 | ||
Avg | -0.43 | -0.67 | -0.51 | ||
Low | -0.62 | -1.27 | -0.81 |
EPS Growth
EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
---|---|---|---|---|---|
High | - | - | - | ||
Avg | - | - | - | ||
Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.